<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03691805</url>
  </required_header>
  <id_info>
    <org_study_id>tDCS-TUD</org_study_id>
    <nct_id>NCT03691805</nct_id>
  </id_info>
  <brief_title>Transcranial Direct Current Stimulation - Tobacco Use Disorder</brief_title>
  <official_title>Transcranial Direct Current Stimulation as an Intervention in Tobacco Use Disorder: Effects on Consumption and Craving</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Institute of Mental Health, Mannheim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Institute of Mental Health, Mannheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to detect how transcranial direct current stimulation (tDCS) affects smokers'
      inhibitory control, craving and consumption of tobacco goods.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participating smokers are to receive anodal transcranial direct current stimulation of the
      right dorsolateral prefrontal cortex (rDLPFC) for 20 minutes on five consecutive days.
      Neuropsychological tests on inhibitory control and interviews on smoking habits and craving
      will be applied before and after the first stimulation as well as after the fifth
      stimulation.

      After a follow-up period of three days, smoking behaviour will be assessed in a telephone
      interview.

      Changes in inhibitory control and smoking behaviour will be compared between an active and a
      sham stimulation group.This way the effects of transcranial direct current stimulation on
      tobacco use disorder are to be clarified.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2018</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Half of the participants will receive transcranial direct current stimulation, while the others will receive sham stimulation.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Participants will be blinded as to their assigned study arm.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Reduced number of cigarettes smoked</measure>
    <time_frame>First assessment on Day 1, second on Day 8</time_frame>
    <description>Smoking habits will be assessed via interview at the beginning of the study and after a follow-up period of three days. Number of cigarettes smoked will be compared longitudinally and between groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduced Carving</measure>
    <time_frame>First assessment on Day 1, second on Day 5, third on Day 8</time_frame>
    <description>Craving will be assessed using visual analog scales on the first and fifth day of the study as well as in the follow-up interview. Ratings will be compared longitudinally and between groups..</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increased inhibitory control</measure>
    <time_frame>First and second testing on Day 1, third testing on Day 5</time_frame>
    <description>Inhibitory control will be assessed in neuropsychological tests (Go / No-Go, Stop-Signal Task) before and after the first stimulation session and after the fifth session. Results will be compared longitudinally and between groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Tobacco Use Disorder</condition>
  <arm_group>
    <arm_group_label>anodal tDCS over rDLPFC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive anodal tDCS (transcranial direct current stimulation) of the right dorsolateral prefrontal Cortex (DLPFC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sham tDCS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Participants will receive sham tDCS (transcranial direct current stimulation) of the DLPFC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>tDCS</intervention_name>
    <description>The participants will receive anodal tDCS (transcranial direct current stimulation) of the right dorsolateral prefrontal cortex for 20 minutes on five consecutive days.</description>
    <arm_group_label>anodal tDCS over rDLPFC</arm_group_label>
    <other_name>sooma medical</other_name>
    <other_name>transcranial direct current stimulation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham tDCS</intervention_name>
    <description>The participants will receive sham tDCS (transcranial direct current stimulation) of the dorsolateral prefrontal cortex for 20 minutes on five consecutive days.</description>
    <arm_group_label>sham tDCS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  tobacco use disorder

          -  normal or correctable eyesight

          -  sufficient ability to communicate with the investigators, to answer questions in oral
             and written form

          -  fully informed consent

          -  written informed consent

        Exclusion Criteria:

          -  withdrawal of the declaration of consent

          -  exclusion criteria for tDCS (metal implants in the head, acute eczema, known epilepsy)

          -  severe internal, neurological or psychiatric comorbidity

          -  pharmacotherapy with psychoactive substances within the last 14 days

          -  axis-I disorder according to ICD-10 and DSM 5 (except tobacco use disorder)

          -  positive urin drug screening (cannabis, amphetamine, opiates, benzodiazepines,
             cocaine)

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sabine Vollstädt-Klein</last_name>
    <role>Principal Investigator</role>
    <affiliation>ZI Mannheim</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sabine Vollstädt-Klein, Prof.(apl.) Dr.</last_name>
    <phone>0621 / 1703 - 3912</phone>
    <email>sabine.vollstaedt-klein@zi-mannheim.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Isabella MS Mayer, Dr.</last_name>
    <phone>0621 / 1703 - 3723</phone>
    <email>isabella.mayer@zi-mannheim.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Klinik für Abhängiges Verhalten, Zentralinstitut für Seelische Gesundheit</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Vollstädt-Klein</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>September 28, 2018</study_first_submitted>
  <study_first_submitted_qc>September 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2018</study_first_posted>
  <last_update_submitted>January 8, 2020</last_update_submitted>
  <last_update_submitted_qc>January 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transcranial Direct Current Stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

